Literature DB >> 7669574

Antibodies against p53 are associated with poor prognosis of colorectal cancer.

J G Houbiers1, S H van der Burg, L M van de Watering, R A Tollenaar, A Brand, C J van de Velde, C J Melief.   

Abstract

Mutation of the p53 gene is a common event in colorectal cancer. This alteration can result in cellular accumulation of p53 and may also induce p53 antibodies. Accumulation of p53 in tumour cells has been associated with poor prognosis of colorectal cancer. We tested preoperative sera from 255 patients with colorectal cancer by enzyme-linked immunosorbent assay (ELISA). A total of 70.2% had reactivity that was higher than the 'low' control serum. Employing a cut-off level of 10% of the 'high' control sample, 25.5% of the patients were positive for p53 antibodies. The presence of p53 antibodies correlated with the following prognostic factors: histological differentiation grade, shape of the tumour, and tumour invasion into blood vessels. Patients with p53 antibodies were shown to have decreased survival and decreased disease-free survival. Specifically for patients with cancer stage A and B1 the presence of p53 antibodies selected a subgroup with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669574      PMCID: PMC2033915          DOI: 10.1038/bjc.1995.386

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  The prognostic significance of direct extension of carcinoma of the colon and rectum.

Authors:  V B ASTLER; F A COLLER
Journal:  Ann Surg       Date:  1954-06       Impact factor: 12.969

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Expression of p53 and 17p allelic loss in colorectal carcinoma.

Authors:  J Cunningham; J A Lust; D J Schaid; G D Bren; H A Carpenter; E Rizza; J S Kovach; S N Thibodeau
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry.

Authors:  Y Remvikos; P Laurent-Puig; R J Salmon; G Frelat; B Dutrillaux; G Thomas
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

6.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma.

Authors:  C Caron de Fromentel; F May-Levin; H Mouriesse; J Lemerle; K Chandrasekaran; P May
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

8.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

Authors:  A M Davidoff; J D Iglehart; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct sublcasses of large T antigen and for similarities among nonviral T antigens.

Authors:  E G Gurney; R O Harrison; J Fenno
Journal:  J Virol       Date:  1980-06       Impact factor: 5.103

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  36 in total

1.  Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.

Authors:  Hiroki Ochiai; Takashi Ohishi; Koji Osumi; Jo Tokuyama; Hidejirou Urakami; Shikou Seki; Atsushi Shimada; Akira Matsui; Yoh Isobe; Yuya Murata; Takashi Endo; Yoshiyuki Ishii; Hirotoshi Hasegawa; Sumio Matsumoto; Yuko Kitagawa
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Tumours can act as adjuvants for humoral immunity.

Authors:  D M Brown; T L Fisher; C Wei; J G Frelinger; E M Lord
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

3.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 4.  Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

Authors:  Albert B DeLeo; Theresa L Whiteside
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

Review 5.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

6.  Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.

Authors:  Rei Okada; Hideaki Shimada; Yuichiro Otsuka; Masaru Tsuchiya; Jun Ishii; Toshio Katagiri; Tetsuya Maeda; Yoshihisa Kubota; Tetsuo Nemoto; Hironori Kaneko
Journal:  Surg Today       Date:  2017-05-15       Impact factor: 2.549

Review 7.  Human antibodies in cancer and autoimmune disease.

Authors:  H J Ditzel
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

8.  Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.

Authors:  Salma Abdelmoula-Souissi; Nourane Zouari; Imen Miladi-Abdenadher; Ouhoud Yaich-Kolsi; Ines Ayadi-Masmoudi; Abdelmajid Khabir; Hatem Masmoudi; Mounir Frikha; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2013-03-26       Impact factor: 2.316

9.  Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.

Authors:  Benjamin Piura; Ettie Piura
Journal:  J Oncol       Date:  2010-01-17       Impact factor: 4.375

10.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.